🟢 BeyondSpring is trading 12.91% up in pre-market — no clear company-specific catalyst identified

BeyondSpring is trading at $0.56, up 12.91%, with no clear positive company-specific catalyst for the pre-market rise identified in search results.

• The XBI is up 3.64% pre-market, while supplied broad-market indicators are down; this does not establish the cause.
• Reports dated October 21 described an FDA rejection of plinabulin, a negative development that does not explain the current rise.
• Pre-market volume and activity details were unavailable.